Neuraminidase glycopeptides are modified versions of the neuraminidase enzyme, which is critical for the replication and release of influenza viruses from infected cells. The glycopeptide variants have enhanced stability and activity. In therapeutic applications, neuraminidase glycopeptides are primarily used in the development of antiviral drugs to combat influenza. Their enhanced stability and effectiveness make them a key component in formulating inhibitors that prevent the spread of the virus and reduce the severity of flu symptoms. Biomedical use of neuraminidase glycopeptides extends to vaccine development and diagnostic tools. By improving the understanding of viral mechanisms and enhancing therapeutic strategies, it plays a crucial role in managing influenza outbreaks and advancing influenza research.
